KRAS and RAS inhibitor trial starts vs Autoimmune cell therapy and T-cell engager trial starts
In 2025, KRAS and RAS inhibitor trial starts worldwide stood at 56, against 112 for autoimmune cell therapy and T-cell engager trial starts.
Change the pair
Compare different indicators
The series
Over time
Global, spaced by time. Both series are in count, so they share one axis; the legend names each line.
KRAS and RAS inhibitor trial starts and Autoimmune cell therapy and T-cell engager trial starts
Unit: count · 12 observations
View the underlying data
| Indicator | Period | Type | Value |
|---|---|---|---|
| KRAS and RAS inhibitor trial starts | 2025 | Actual | 56 |
| KRAS and RAS inhibitor trial starts | 2024 | Actual | 60 |
| KRAS and RAS inhibitor trial starts | 2023 | Actual | 44 |
| KRAS and RAS inhibitor trial starts | 2022 | Actual | 37 |
| KRAS and RAS inhibitor trial starts | 2021 | Actual | 23 |
| KRAS and RAS inhibitor trial starts | 2020 | Actual | 13 |
| Autoimmune cell therapy and T-cell engager trial starts | 2025 | Actual | 112 |
| Autoimmune cell therapy and T-cell engager trial starts | 2024 | Actual | 91 |
| Autoimmune cell therapy and T-cell engager trial starts | 2023 | Actual | 17 |
| Autoimmune cell therapy and T-cell engager trial starts | 2022 | Actual | 6 |
| Autoimmune cell therapy and T-cell engager trial starts | 2021 | Actual | 7 |
| Autoimmune cell therapy and T-cell engager trial starts | 2020 | Actual | 2 |
Shared periods
Side by side
6 periods are published for both series as annual figures on the same basis. Comparing anything else would mean comparing different periods.
| Period | KRAS and RAS inhibitor trial starts | Autoimmune cell therapy and T-cell engager trial starts |
|---|---|---|
| 2020 | 13 ClinicalTrials.gov | 2 ClinicalTrials.gov |
| 2021 | 23 ClinicalTrials.gov | 7 ClinicalTrials.gov |
| 2022 | 37 ClinicalTrials.gov | 6 ClinicalTrials.gov |
| 2023 | 44 ClinicalTrials.gov | 17 ClinicalTrials.gov |
| 2024 | 60 ClinicalTrials.gov | 91 ClinicalTrials.gov |
| 2025 | 56 ClinicalTrials.gov | 112 ClinicalTrials.gov |
Provenance
Where these numbers come from
KRAS and RAS inhibitor trial starts
Count of interventional studies whose record names a KRAS or RAS inhibitor (G12C, G12D, pan-KRAS and pan-RAS agents) whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Autoimmune cell therapy and T-cell engager trial starts
Count of interventional studies of CAR-T, CAR-NK or T-cell-engager therapies in autoimmune conditions, excluding records that also list a cancer whose start date falls in the period. The region is a site country: a study counts for every country where it lists a site, so regional counts overlap and do not sum to the global count.
6 observations charted in Global · source organisations: ClinicalTrials.gov
Data published under CC BY 4.0. Series A as JSON · Series B as JSON
Keep exploring